Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections


SILVER SPRING, Md., July 17, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

"The FDA remains focused on facilitating the development of safe and effective new antibacterial drugs to give patients more options to fight serious infections," said Ed Cox, M.D., M.P.H., director for the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. "It is important that the use of Recarbrio be reserved for situations when there are limited or no alternative antibacterial drugs for treating a patient's infection." 

Recarbrio is a three-drug combination injection containing imipenem-cilastatin, a previously FDA-approved antibiotic, and relebactam, a new beta-lactamase inhibitor.

The determination of efficacy of Recarbrio was supported in part by the findings of the efficacy and safety of imipenem-cilastatin for the treatment of cUTI and cIAI. The contribution of relebactam to Recarbrio was assessed based on data from in vitro studies and animal models of infection. The safety of Recarbrio, administered via injection, was studied in two trials, one each for cUTI and cIAI. The cUTI trial included 298 adult patients with 99 treated with the proposed dose of Recarbrio. The cIAI trial included 347 patients with 117 treated with the proposed dose of Recarbrio.

The most common adverse reactions observed in patients treated with Recarbrio included nausea, diarrhea, headache, fever and increased liver enzymes.

Recarbrio should not be used in patients taking ganciclovir unless the benefits outweigh the risks as generalized seizures have been reported. Patients should also avoid using Recarbrio when taking valproic acid or divalproex sodium, drugs used to manage seizures, as a reduction in valproic acid level may lead to seizures.

Recarbrio received FDA's Qualified Infectious Disease Product (QIDP) designation. The QIDP designation is given to antibacterial and antifungal drug products intended to treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act. As part of QIDP designation, Recarbrio was granted Priority Review under which the FDA's goal is to take action on an application within an expedited time frame.

The FDA granted the approval of Recarbrio for the treatment to Merck & Co., Inc.

A key global challenge the FDA faces as a public health agency is addressing the threat of antimicrobial-resistant infections. Among the FDA's other efforts to address antimicrobial resistance, is the focus on facilitating the development of safe and effective new treatments to give patients more options to fight serious infections.

For more information:

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Alison Hunt, 240-402-0764, alison.hunt@fda.hhs.gov

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 15:44
Canopy Growth Corporation ("Canopy Growth" or the "Company") is pleased to announce that effective January 14, 2020, David Klein has been appointed as the Company's Chief Executive Officer. David brings a wealth of...

at 15:41
Montreal's innovation professionals are coming together to provide an advanced technological solution to help care more effectively for patients with heart failure and multiple other conditions such as diabetes. Called...

at 15:36
The Accreditation Council for Graduate Medical Education's (ACGME's) Clinical Learning Environment Review (CLER) Program is pleased to announce the publication of Version 2.0 of its CLER Pathways to Excellence: Expectations for an Optimal Clinical...

at 15:30
The Financing and Reimbursement of Cures in the US Consortium (FoCUS) launched the Paying for Cures Toolkit today. The free online resource helps payers, patient advocates, drug developers, policymakers, and other healthcare system stakeholders...

at 15:24
Canada's largest union, the Canadian Union of Public Employees (CUPE), is calling on Prime Minister Justin Trudeau to restore federal health funding increases through the Canada Health Transfer (CHT) to 2016 levels. CUPE...

at 15:21
Portola Pharmaceuticals, Inc.® today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refractory follicular lymphoma (FL) receiving...



News published on 17 july 2019 at 08:43 and distributed by: